SEC Form 4 · accession 0001209191-18-063713
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason Hoitt
Officer — Chief Commercial Officer
Period of report
Dec 19, 2018
Accepted (ET)
Dec 20, 2018 · 5:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 19, 2018 | A | 24,711 | — | A | 24,711 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $6.07 | Dec 19, 2018 | A | 250,000 | A | — | Dec 18, 2028 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1Represents a restricted stock unit ("RSU") award that vests 25% on each of March 29, 2019, June 28, 2019, September 30, 2019 and December 31, 2019.
- F2Each RSU represents a contingent right to receive one share of Issuer common stock.
- F325% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date.